# Indian Patent Office rejects patent application for BPaL drug combination used against drug-resistant tuberculosis

*The rejection may enable wider generic competition for the six-month, all-oral BPaL regimen, although lower prices and universal availability are not automatic.*

**Society, Public Health and Intellectual Property · 2 Nov 2026 · GS: GS2, GS3, Essay · Exam yield: High**

*Written by the automatic desk. Not checked by a person.*

## Why this matters

This decision connects three UPSC themes: treatment of drug-resistant tuberculosis, access to essential medicines, and the balance between patent protection and public health. It may widen the field for Indian manufacturers, but patients benefit only if regulators, procurement systems and the national programme convert legal space into reliable treatment access.

## In plain words

This story sits at the intersection of public health and intellectual property. Tuberculosis bacteria can become resistant to important medicines, making treatment longer, costlier and harder to complete. For eligible patients, BPaL is a six-month, all-oral combination of bedaquiline, pretomanid and linezolid; when moxifloxacin is added, the combination is called BPaLM. Current World Health Organization guidance generally prefers BPaLM for suitable patients, while BPaL is particularly relevant when resistance to fluoroquinolones is present. WHO guidance also limits use according to age, disease site, pregnancy status and previous exposure to the medicines. [WHO Consolidated Guidelines, 2025] ([tbksp.who.int](https://tbksp.who.int/en/node/3033?utm_source=openai))

The Indian Patent Office rejected a patent application filed by the Global Alliance for TB Drug Development, commonly called TB Alliance, for the BPaL combination. Two pre-grant oppositions had challenged the application before the patent was granted. Rejection means this particular application cannot give the applicant exclusive patent rights over the combination in India. That removes one possible legal obstacle for Indian manufacturers and may encourage competition. [The Indian Express, 31 October 2026] ([indianexpress.com](https://indianexpress.com/article/explained/explained-health/tb-drug-patent-rejection-india-treatment-costs-10943445/lite/))

The practical lesson is that patent rejection is an opportunity, not an instant price cut. Manufacturers still need regulatory permission, quality assurance, production capacity and procurement orders. The government must also identify eligible patients, conduct drug-resistance testing, monitor side effects and prevent interruptions. Think of the patent as a locked gate: opening it allows more suppliers to enter, but affordable and dependable treatment still requires roads, vehicles and functioning public distribution.

## Key facts

- BPaL combines bedaquiline, pretomanid and linezolid for eligible patients with drug-resistant tuberculosis.
- The patent application was filed by the US-based TB Alliance and faced pre-grant oppositions in India.
- The rejection removes one potential legal barrier to Indian manufacturers producing the combination.
- BPaL is a shorter, all-oral regimen compared with many older drug-resistant TB treatments.
- Patent rejection alone does not guarantee immediate price reductions, regulatory approval or uninterrupted availability.

## How we got here

India’s tuberculosis policy has increasingly shifted from long, toxic and sometimes injection-based treatment towards shorter, all-oral combinations. In December 2022, the World Health Organization recommended a six-month BPaLM regimen for eligible people with multidrug-resistant or rifampicin-resistant tuberculosis; where fluoroquinolone resistance is confirmed, moxifloxacin may be omitted and BPaL used. The 2025 WHO guidance retained BPaL-based options while refining eligibility, monitoring and possible extension of BPaL to nine months in selected cases. ([who.int](https://www.who.int/news/item/15-12-2022-who-announces-landmark-changes-in-treatment-of-drug-resistant-tuberculosis?utm_source=openai))

The Indian application was opposed in 2020 by patient and public-health groups, including organisations associated with Sankalp Rehabilitation Trust, the Delhi Network of Positive People, Lawyers Collective, Médecins Sans Frontières Access Campaign and Third World Network. A pre-grant opposition allows a person or organisation to challenge a patent application before grant. The controversy reflects concern that additional patents on known medicines or formulations may delay competition, a practice often described as evergreening. The decision follows earlier Indian refusals concerning certain bedaquiline-related applications, according to The Indian Express. ([indianexpress.com](https://indianexpress.com/article/explained/explained-health/tb-drug-patent-rejection-india-treatment-costs-10943445/lite/))

## The bigger picture

**Constitutional — Right to health and state obligation**

The Constitution does not expressly name a fundamental right to health, but the Supreme Court has read health and medical care into the right to life under Article 21. A patent decision does not itself provide treatment; the state must translate legal access into diagnosis, procurement, free public treatment and continuity of care. The issue therefore combines individual dignity with the government’s duty to use public resources fairly. The strongest constitutional argument is not that every medicine must be free instantly, but that avoidable legal and administrative barriers should not deny life-saving care.

→ Patent flexibility matters constitutionally only when it is converted into actual, non-discriminatory access.

**Economic — Competition, procurement and price**

Patent rejection can permit more manufacturers to seek approval for the combination, increasing competition and bargaining power in government procurement. However, price depends on manufacturing cost, regulatory timelines, quality requirements, supplier numbers, order volumes and uninterrupted supply. The Indian Express reported that a six-month BPaLM course had fallen from 588 US dollars in 2022 to 284 US dollars after earlier competition involving bedaquiline, but this does not prove that the present decision alone caused a similar fall. The immediate budgetary gain may accrue mainly to government, since public-sector patients receive medicines free.

→ Competition creates the possibility of lower prices; procurement design determines whether that possibility becomes savings.

**Social — Treatment burden and inequality**

Drug-resistant tuberculosis imposes more than a medicine cost: patients may lose wages, travel repeatedly to treatment centres, face stigma and struggle with adverse effects. A six-month oral regimen can reduce treatment fatigue compared with older regimens involving longer courses and injections. Yet eligibility restrictions, delayed diagnosis, weak counselling and unequal access to testing can exclude precisely those who need newer treatment most. Lower procurement prices should therefore be paired with nutrition support, travel assistance, patient counselling and community-based follow-up.

→ Shorter treatment improves the chance of completing care, but social barriers can still defeat medical innovation.

**Science & Tech — Eligibility, resistance and safety**

BPaL is not a universal tuberculosis treatment. It is intended for selected patients whose disease and resistance pattern make the medicines appropriate; testing for resistance to fluoroquinolones is strongly encouraged. WHO excludes or cautions against use in several situations, including some central nervous system, bone and joint, disseminated, pregnancy and prior-drug-exposure contexts. Linezolid can cause important adverse effects, so clinical monitoring is essential. Wider production must never mean weaker testing, poor-quality batches or indiscriminate prescription, because misuse can create further resistance.

→ The access goal is not maximum distribution, but correct treatment for the right patient with monitoring.

**International — India’s generic and access role**

India is a major supplier of affordable medicines to developing countries, so an Indian patent decision may influence access beyond domestic patients if manufacturers obtain required approvals for export. The case illustrates the policy space available under international patent rules to prevent unwarranted monopolies while preserving genuine innovation. It also highlights a global tension: new medicines require investment, but excessive exclusivity can delay affordable treatment for diseases concentrated in poorer populations. India’s credibility depends on combining strong patent examination with dependable quality regulation.

→ India’s public-health patent approach has global consequences because its manufacturers serve many low- and middle-income countries.

## The big debate

**Does rejection of the BPaL patent represent the right balance between innovation and public-health access?**

**For**
- It removes a possible monopoly, encourages competition and may reduce government procurement costs for a high-burden disease.
- Pre-grant opposition gives patients and civil society a lawful voice before exclusive rights are created.
- Preventing weak or repetitive patents protects the effectiveness of India’s generic medicine sector.

**Against**
- Repeated patent rejection can reduce expected returns for research into difficult diseases and future drug development.
- Competition without strong regulatory oversight may create quality problems, misleading marketing or fragmented supply.
- Patent rejection alone cannot solve affordability if only a few firms can manufacture or obtain approval.

**The balanced take:** The rejection is defensible where the claimed combination does not satisfy India’s patent standards, especially for a serious public-health need. But it should not be presented as an automatic cure for high prices. India must protect genuine innovation while ensuring transparent examination, quality control, competitive procurement and uninterrupted treatment for eligible patients.

## Answer it in Mains

**How can intellectual property protection be balanced with access to essential medicines in India? Discuss with reference to the BPaL patent decision.** *(GS2)*

How to attack it: Begin with the public-health importance of drug-resistant tuberculosis; examine patent incentives, patentability standards, pre-grant opposition and constitutional access; conclude with quality-assured competition and lawful safeguards.

Quote this: The Patents Act, 1970; pre-grant opposition framework; Indian Express report on the 2026 BPaL decision ([indiacode.nic.in](https://www.indiacode.nic.in/bitstream/123456789/1392/3/A1970-39.pdf?utm_source=openai))

**Drug-resistant tuberculosis is both a public-health challenge and an antimicrobial-resistance challenge. Examine India’s policy priorities.** *(GS2)*

How to attack it: Define drug-resistant tuberculosis; link delayed diagnosis, treatment burden and treatment interruption with resistance; assess shorter regimens, testing, procurement and patient support; conclude with an integrated national response.

Quote this: WHO Consolidated Guidelines on Tuberculosis, Module 4, 2025; WHO recommendation on six-month BPaLM and BPaL-based treatment ([who.int](https://www.who.int/publications/i/item/9789240107243?utm_source=openai))

**Patent rejection does not automatically ensure affordable healthcare. Explain the institutional steps required to convert legal access into treatment access.** *(GS3)*

How to attack it: Use the rejected patent as the introduction; distinguish patent rights from drug approval; analyse manufacturing, quality assurance, procurement, supply chains and clinical monitoring; conclude with measurable access indicators.

Quote this: WHO guidance on regimen eligibility, treatment duration and supply-related implementation; Indian Express discussion of price and procurement limits ([tbksp.who.int](https://tbksp.who.int/en/node/3033?utm_source=openai))

**Shorter treatment regimens can improve health outcomes, but social determinants often decide treatment completion. Discuss.** *(Essay)*

How to attack it: Open with the contrast between a shorter oral regimen and the lived burden of prolonged therapy; connect poverty, stigma, travel and lost wages with adherence; conclude that medical innovation must be socially delivered.

Quote this: WHO notes that shorter treatment reduces patient, household and health-system burden; Indian Express records continuing travel, nutrition and income costs ([tbksp.who.int](https://tbksp.who.int/en/node/3032?utm_source=openai))

## Prelims quick-fire

- **[Term]** BPaL contains bedaquiline, pretomanid and linezolid; BPaLM adds moxifloxacin to the same three-medicine combination. — *The final letter M denotes moxifloxacin, not a separate treatment duration.*
- **[International]** The World Health Organization recommended six-month all-oral BPaLM treatment for eligible drug-resistant tuberculosis patients in 2022. — *WHO guidance is conditional and eligibility-based, not a universal prescription.*
- **[ScientificTech]** BPaL may be used when fluoroquinolone resistance is confirmed and moxifloxacin therefore cannot contribute effectively. — *Resistance testing and clinical judgement remain necessary before selecting the regimen.*
- **[Term]** A pre-grant opposition challenges a patent application before the patent is granted; it is not a court appeal after grant. — *The Indian Patents Act, 1970 contains the statutory opposition framework.*
- **[Body/Institution]** The Indian Patent Office rejected the BPaL combination application filed by the Global Alliance for TB Drug Development. — *Rejection of one application does not cancel every possible patent relating to individual medicines.*
- **[Data]** India’s tuberculosis incidence rate was reported as 187 cases per 100,000 people in 2024 by The Indian Express. — *Incidence means new cases arising in a population during a specified period, not total existing cases.*
- **[Report/Index]** WHO’s 2025 guidance generally prefers BPaLM for eligible patients and permits BPaL-based treatment in specified circumstances. — *Do not write that BPaL has replaced all longer regimens for every patient.*
- **[Economic]** Public-sector tuberculosis patients may receive medicines free, so lower prices initially reduce government procurement expenditure. — *Patients can still face travel, nutrition, investigation and lost-income costs.*

## What should happen

1. **Publish a clear implementation pathway for manufacturers covering regulatory approval, quality testing, pharmacovigilance and public procurement.** Legal freedom to manufacture is useful only when capable suppliers can enter quickly without weakening safety standards. *(WHO Consolidated Guidelines on Tuberculosis, Module 4, 2025 ([who.int](https://www.who.int/publications/i/item/9789240107243?utm_source=openai)))*
2. **Use pooled, transparent and multi-supplier procurement for eligible BPaL and BPaLM medicines.** Several qualified suppliers can reduce dependence on one company, improve bargaining power and lower the risk of stock-outs. *(WHO Consolidated Guidelines on Tuberculosis, Module 4, 2025 ([tbksp.who.int](https://tbksp.who.int/en/node/3033?utm_source=openai)))*
3. **Expand rapid resistance testing and decentralised treatment support under the National Tuberculosis Elimination Programme.** Correct eligibility decisions and nearby follow-up are essential because BPaL is not suitable for every patient. *(WHO Consolidated Guidelines on Tuberculosis, Module 4, 2025 ([tbksp.who.int](https://tbksp.who.int/en/node/3033?utm_source=openai)))*
4. **Monitor prices, supplier concentration, treatment outcomes, adverse effects and interruptions through publicly reported indicators.** Transparent evidence will show whether patent rejection actually improves affordability, quality and continuity rather than merely changing legal status. *(Sustainable Development Goal 3.3)*
5. **Preserve rigorous patent examination while using lawful public-health safeguards against unjustified extension of exclusivity.** India needs both incentives for genuine pharmaceutical innovation and timely access to essential medicines. *(The Patents Act, 1970, especially its provisions on patentability and opposition ([indiacode.nic.in](https://www.indiacode.nic.in/bitstream/123456789/1392/3/A1970-39.pdf?utm_source=openai)))*

## Jargon, demystified

- **BPaL and BPaLM** — BPaL is bedaquiline, pretomanid and linezolid; BPaLM adds moxifloxacin to the same combination. *(Remember: M stands for moxifloxacin.)*
- **Drug-resistant tuberculosis and MDR/RR-TB** — Tuberculosis that does not respond to important medicines; MDR/RR-TB means multidrug-resistant or rifampicin-resistant tuberculosis. *(MDR means resistance to at least isoniazid and rifampicin; RR means resistance to rifampicin.)*
- **Patent and generic medicine** — A patent gives time-limited exclusive rights over an invention; a generic medicine is a comparable product made after lawful entry. *(Patent rejection does not itself grant regulatory permission to sell.)*
- **Pre-grant opposition** — A formal challenge filed before a patent is granted, allowing affected persons or organisations to question patentability. *(It is different from challenging a patent after grant.)*
- **Evergreening** — Seeking additional protection for minor changes to an existing medicine or formulation, potentially delaying competition. *(It is a policy concern, not automatically proof that every later patent is invalid.)*
- **World Health Organization and National Tuberculosis Elimination Programme** — The World Health Organization issues global health guidance; India’s National Tuberculosis Elimination Programme implements national tuberculosis control policy. *(Guidance must still be adapted through Indian regulatory and programme decisions.)*
- **Drug susceptibility testing and regulatory approval** — Drug susceptibility testing checks which medicines can work against a patient’s tuberculosis; regulatory approval permits specified medical use or sale. *(Neither patent rejection nor WHO guidance replaces patient testing and Indian regulatory permission.)*

## Revise in 30 seconds

- BPaL combines bedaquiline, pretomanid and linezolid; BPaLM adds moxifloxacin.
- Patent rejection removes one possible exclusivity barrier, not all barriers to sale or supply.
- WHO guidance makes treatment eligibility-dependent; BPaL is not for every tuberculosis patient.
- Lower medicine prices may first benefit government procurement because public treatment is free.
- Shorter oral treatment can reduce injections, treatment fatigue, lost wages and treatment interruption.
- Access requires competition, quality assurance, resistance testing, procurement and uninterrupted follow-up.

## Study next

**Static links:** Right to life and public health, Intellectual property and pharmaceutical patents, Antimicrobial resistance and health-system governance, Affordable access to essential medicines

**Essay angle:** A patent gate may be opened by law, but public health improves only when the state builds the road from manufacture to the patient.

**Interview probe:** How would you ensure that wider generic competition lowers costs without compromising medicine quality or encouraging inappropriate use?

## Sources

- [Explained: Why India’s rejection of a TB drug patent matters for patients](https://indianexpress.com/article/explained/explained-health/tb-drug-patent-rejection-india-treatment-costs-10943445/lite/)

---

*Source: "Indian Patent Office rejects patent application for BPaL drug combination used against drug-resistant tuberculosis" — Minds of Aspirants. Canonical URL: https://mindsofaspirants.com/current-affairs/kx763vqdqb0rbzk5rxhnpea0p58hf8zt. When citing, quoting, or reusing this content, please credit Minds of Aspirants and link back to this URL.*